Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

This study reports that a new mouse model with a CARD14 mutation successfully mimics key human PRP symptoms, and anti-IL-17A antibody significantly reduces these symptoms.

This review summarizes current knowledge on the role of the JAK/STAT signaling pathway in alopecia areata and suggests moderate efficacy of systemic inhibitors, with low adverse events but high recurrence rates.

This study found that type I interferon response-related genes activated by RIG-1 and IL-17 pathways were significantly up-regulated in hair follicle and skin samples with chronic discoidal lupus erythematosus.

This review outlines the proposed theories behind the development of alopecia areata, emphasizing the autoimmune process involving lost immune privilege in hair follicles, and stresses the need to pinpoint specific pathogenic mechanisms for potential treatments.

This study suggests that dietary grape powder may reduce the severity of atopic dermatitis in a mouse model, highlighting its potential in both prevention and intervention settings.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This review examines targeting the JAK-STAT pathway in inflammatory skin diseases, highlighting existing JAK inhibitors and potential developments, but presents no new experimental or clinical results.

This review covers presentations from the 68th Annual Meeting of the Society of Investigative Dermatology and highlights research advances in dermatology, but reports no new clinical results.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

This review discusses the role of regulatory T-cells in tissue repair and regeneration across various organs and reports no new clinical results.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

This study found that the cytokine-mediated signaling pathway is the primary pathway disrupted in skin after CO2 laser surgery.

This review summarizes recent findings on how the dysregulated PI3K/Akt/mTOR pathway contributes to immune-mediated inflammatory skin disorders and discusses the potential of natural products, synthetic compounds, and biologic agents in their treatment. However, it emphasizes the need for further research to develop effective therapies.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This review discusses the classification, diagnosis, and potential treatment pathways for Alopecia Areata, emphasizing the complex genetic and immunological factors involved, but reports no new clinical results.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This study found that inhibiting the Hedgehog pathway may reduce proliferation and migration in melanoma, suggesting its potential repurposing as a therapeutic target.

This study demonstrated that SHFKO significantly accelerated healing in acute radiation-induced skin injuries, with mechanisms involving apoptosis inhibition, suppression of inflammation, and restoration of ROS balance, suggesting its potential as a novel multi-target therapy for radiodermatitis.

This review discusses the pathophysiology of alopecia areata, highlighting the role of CD8 cytotoxic T cells and the upregulation of JAK signaling pathways; it reports no new experimental results.

In this study, type I interferon response-related genes activated by RIG-1 and IL-17 signaling pathways were significantly up-regulated in both hair follicles and skin tissues affected by chronic discoidal lupus erythematosus.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

This study found that certain T cell-associated genes were upregulated in dogs with Vogt-Koyanagi-Harada syndrome and vitiligo, suggesting a shared immunopathogenesis with humans.

Alopecia areata patients are more likely to develop keloids, especially if they also have atopic dermatitis.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

This article reviews current and emerging treatments for alopecia areata, emphasizing the need for biomarker-driven patient stratification to optimize therapeutic strategies and reduce potential side effects; it reports no new clinical findings.

In this study, researchers demonstrated that CD4 T cells from skin-draining lymph nodes in mice with alopecia areata can transfer the disease to recipient mice, revealing a critical role for CD4 T cells in disease development and suggesting potential therapeutic targets.

This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.